Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Iobenguane. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.84 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.84 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.84 |
| ▸ | THPO | P40225 | 1/20 | 0.84 |
| ▸ | RAB9A | P51151 | 1/20 | 0.84 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.84 |
| ▸ | GRIN2B | Q13224 | 6/20 | 0.61 |
| ▸ | GRIN2D | O15399 | 2/20 | 0.61 |
| ▸ | GRIN3B | O60391 | 2/20 | 0.61 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.61 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.61 |
| ▸ | GRIN2C | Q14957 | 2/20 | 0.61 |
| ▸ | GRIN3A | Q8TCU5 | 2/20 | 0.61 |
| ▸ | HTR3E | A5X5Y0 | 2/20 | 0.60 |
| ▸ | HTR3B | O95264 | 2/20 | 0.60 |
| ▸ | HTR3A | P46098 | 2/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Iobenguane SCHEMBL29722658 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2LMNAPMP22CYP1A2CYP2D6 | |
| Iobenguane SCHEMBL29435410 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2LMNAPMP22CYP1A2CYP2D6 | |
| Iobenguane SCHEMBL140592 | 0.92 | CYP1A2 (1.00) | SMN1; SMN2LMNAPMP22CYP1A2CYP2D6 | |
| Iobenguane SCHEMBL16040804 | 0.90 | CYP1A2 (0.96) | SMN1; SMN2LMNAPMP22CYP1A2CYP2D6 | |
| Iobenguane I 123 SCHEMBL30040171 | 0.79 | HTR1A (0.81) | SMN1; SMN2LMNAPMP22CYP1A2CYP2D6 | |
| Sulfuric Acid SCHEMBL4014387 | 0.79 | LMNA (0.65) | SMN1; SMN2LMNAPMP22CYP1A2CYP2D6 | |
| SCHEMBL3927834 | 0.75 | HIF1A (0.69) | SMN1; SMN2LMNAPMP22CYP1A2CYP2D6 | |
| Hydrochloric Acid SCHEMBL538276 | 0.74 | HTR3E (0.96) | SMN1; SMN2LMNAPMP22CYP1A2CYP2D6 | |
| M-Fluorobenzylguanidine SCHEMBL11882096 | 0.74 | TAAR1 (0.60) | SMN1; SMN2LMNAPMP22CYP1A2CYP2D6 | |
| SCHEMBL4811258 | 0.73 | LMNA (0.57) | SMN1; SMN2LMNAPMP22CYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5019323-A | Radioactive drug | KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTRE (SA) | 1991-05-28 | — | — | US | claimed |
| US-20240024518-A1 | CONTRAST AGENT AND PRECURSOR AND MANUFACTURING METHOD THEREOF | INSTITUTE OF NUCLEAR ENERGY RESEARCH, ATOMIC ENERGY COUNCIL, EXECUTIVE YUAN (TW) | 2024-01-25 | — | — | US | disclosed |
| US-9221029-B2 | Automatic system for synthesizing 123I-MIBG and automatic device for synthesizing and dispensing 123I-MIBG comprising the same | INSTITUTE OF NUCLEAR ENERGY RESEARCH ATOMIC ENERGY COUNCIL, EXECUTIVE YUAN (TW) | 2015-12-29 | — | — | US | disclosed |
| US-20150056105-A1 | AUTOMATIC SYSTEM FOR SYNTHESIZING 123I-MIBG AND AUTOMATIC DEVICE FOR SYNTHESIZING AND DISPENSING 123I-MIBG COMPRISING THE SAME | INSTITUTE OF NUCLEAR ENERGY RESEARCH ATOMIC ENERGY COUNCIL, EXECUTIVE YUAN (TW) | 2015-02-26 | — | — | US | disclosed |
| US-5021220-A | Haluaromatic compound, water-soluble acid, copper salt acid-stable reducing agent | MALLINCKRODT, INC. (US) | 1991-06-04 | — | — | US | disclosed |
| US-5019323-A | Radioactive drug | KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTRE (SA) | 1991-05-28 | — | — | US | disclosed |
| US-4942231-A | CATALYTIC HALOGENATION IN THE PRESENCE OF A REDUCING AGENT AND ACID MEDIUM | MALLINCKRODT, INC. (US) | 1990-07-17 | — | — | US | disclosed |
| EP-0165630-B1 | METHOD OF PREPARING A CHLORINATED, BROMINATED, RADIOBROMINATED, IODINATED AND/OR RADIOIODINATED, AROMATIC OR HETEROAROMATIC COMPOUND, AS WELL AS A KIT FOR PREPARING A DIAGNOSTIC COMPOSITION ON THE BASIS OF THIS COMPOUND | MALLINCKRODT, INC.(a Missouri corporation) (US) | 1989-10-18 | — | — | EP | disclosed |
| EP-0288284-A2 | Method of producing iodine 124 and meta-iodobenzylguanidine containing iodine 124 | KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTRE (SA) | 1988-10-26 | — | — | EP | disclosed |
| US-4584187-A | RADIOIODINATED METAIODOBENZYL GUANIDINE;DIAGNOSS AND TREASTMENT OF HEART, ADRENAL MEDULLA, TUMORS | WIELAND DONALD M | 1986-04-22 | — | — | US | disclosed |
| EP-0165630-A2 | Method of preparing a chlorinated, brominated, radiobrominated, iodinated and/or radioiodinated, aromatic or heteroaromatic compound, as well as a kit for preparing a diagnostic composition on the basis of this compound | MALLINCKRODT, INC.(a Missouri corporation) (US) | 1985-12-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150056105-A1 | AUTOMATIC SYSTEM FOR SYNTHESIZING 123I-MIBG AND AUTOMATIC DEVICE FOR SYNTHESIZING AND DISPENSING 123I-MIBG COMPRISING THE SAME | BPGM, POLG, PIK3CG | SLC6A2 34/4885SMN1; SMN2 4285/4885LMNA 4883/4885 |
| US-20240024518-A1 | CONTRAST AGENT AND PRECURSOR AND MANUFACTURING METHOD THEREOF | TNNT2, NPPA, VHL | SLC6A2 10/4885SMN1; SMN2 98/4885LMNA 573/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.